| scholarly article | Q13442814 |
| P50 | author | Stephan C Schürer | Q41810991 |
| Saurabh Mehta | Q57023917 | ||
| Bryce K Allen | Q86771443 | ||
| P2093 | author name string | Nagi G Ayad | |
| Ernst Schönbrunn | |||
| Stuart W J Ember | |||
| Jin-Yi Zhu | |||
| P2860 | cites work | Selective inhibition of BET bromodomains | Q24301009 |
| MolProbity: all-atom structure validation for macromolecular crystallography | Q24649111 | ||
| PHENIX: a comprehensive Python-based system for macromolecular structure solution | Q24654617 | ||
| Computational methods in drug discovery | Q26997089 | ||
| Suppression of inflammation by a synthetic histone mimic | Q27665789 | ||
| Discovery and characterization of small molecule inhibitors of the BET family bromodomains | Q27667834 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit | Q27674710 | ||
| Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides | Q27675917 | ||
| Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family | Q27675927 | ||
| Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening | Q27680134 | ||
| Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains | Q27680405 | ||
| RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain | Q27680635 | ||
| Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors | Q27681896 | ||
| Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors | Q27684210 | ||
| Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain | Q27684285 | ||
| Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains | Q27685477 | ||
| XDS | Q27860472 | ||
| Phasercrystallographic software | Q27860930 | ||
| The Protein Data Bank: a computer-based archival file for macromolecular structures | Q27860989 | ||
| Features and development of Coot | Q27861079 | ||
| Drug Discovery Targeting Bromodomain-Containing Protein 4. | Q30352390 | ||
| phenix.model_vs_data: a high-level tool for the calculation of crystallographic model and data statistics | Q33637477 | ||
| Folding funnels and binding mechanisms | Q33743626 | ||
| PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains | Q34338531 | ||
| [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains | Q34390229 | ||
| The midpoint method for parallelization of particle simulations | Q34527729 | ||
| Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing | Q34977641 | ||
| BET bromodomain proteins are required for glioblastoma cell proliferation. | Q35086848 | ||
| Implications of protein flexibility for drug discovery | Q35167908 | ||
| Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. | Q36310219 | ||
| Accurate calculation of the absolute free energy of binding for drug molecules | Q36427764 | ||
| Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. | Q37334404 | ||
| Bromodomains and their pharmacological inhibitors | Q38185355 | ||
| Epigenetic pathways and glioblastoma treatment: insights from signaling cascades | Q38257711 | ||
| Lysine acetylation and cancer: A proteomics perspective | Q38982023 | ||
| BET bromodomain inhibition of MYC-amplified medulloblastoma. | Q39050679 | ||
| Inhibitors of the Cdc34 acidic loop: A computational investigation integrating molecular dynamics, virtual screening and docking approaches. | Q40466750 | ||
| Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening | Q40639078 | ||
| Monte Carlo loop refinement and virtual screening of the thyroid-stimulating hormone receptor transmembrane domain | Q41617618 | ||
| Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking | Q42251037 | ||
| A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4. | Q42380933 | ||
| Relative Binding Free Energy Calculations Applied to Protein Homology Models | Q48050957 | ||
| Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. | Q51791975 | ||
| An Integrated In Silico Method to Discover Novel Rock1 Inhibitors: Multi- Complex-Based Pharmacophore, Molecular Dynamics Simulation and Hybrid Protocol Virtual Screening | Q53394392 | ||
| Epigenetics and Human Disease. | Q55113211 | ||
| Comparison of Shape-Matching and Docking as Virtual Screening Tools | Q56853909 | ||
| Structure-based virtual screening of novel, high-affinity BRD4 inhibitors | Q57163250 | ||
| Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field | Q86825224 | ||
| Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation | Q86901887 | ||
| Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors | Q87381077 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 4760-4771 | |
| P577 | publication date | 2017-08-21 | |
| P1433 | published in | ACS Omega | Q27727647 |
| P1476 | title | Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations | |
| P478 | volume | 2 |
Search more.